James Green Chief Executive Officer
Mr. Green joined Avolynt as CEO in 2016. He previously served as Chairman and CEO of Islet Sciences, Inc., a publicly traded biotech focused on developing therapeutic and diagnostic product candidates for diabetes indications. Prior to Islet Sciences, Mr. Green was CEO of BHV Pharma, a clinical stage pharmaceutical company focused on developing novel therapeutics for metabolic diseases. Before founding BHV, James spent several years at GlaxoSmithKline in business development and finance roles. Prior to GSK, Mr. Green advised on M&A, financings, and other strategic alternatives while at Citigroup, Bank of America, and Ernst & Young. Mr. Green also served as a member of the Institutional Care and Use Committee at Duke University Medical Center and on the boards of Pharmacogenetics for Every Nation Initiative, Golden Helix, and Nuada Pharmaceuticals. James earned bachelor of business administration from the University of North Florida and an MBA with a concentration in corporate finance from the Katz Graduate School of Business at The University of Pittsburgh.
Bill Wilkison, Ph.D. Chief Scientific Officer
Dr. Wilkison joined Avolynt as Chief Scientific Officer in 2016. He previously served as Chief Operating Officer of Islet Sciences, Inc., a publicly traded biotech focused on developing therapeutic and diagnostic product candidates for diabetes indications. Prior to Islet Sciences, Bill was Chief Scientific Officer at BHV Pharma, a clinical stage pharmaceutical company. Prior to founding BHV, Dr. Wilkison spent several years at GlaxoSmithKline in worldwide business development. Prior to GSK, Bill was founder and Chief Operating Officer at Artecel, Inc. an adipose-derived stem cell discovery company. Bill was also a founder of Zen-Bio, Inc. a biotech company focused on the development and commercialization of human adipose cells. Prior to Zen-Bio, Bill spent 6 years at Glaxo/GlaxoWellcome studying metabolic disease and was responsible for target/lead identification and development. Dr. Wilkison has published numerous peer-reviewed manuscripts in the metabolic disease area and is an inventor on several approved patents. Dr. Wilkison holds a Ph.D. from Duke University Medical Center and did his postdoctoral work at Harvard Medical School.
Steve Delmar Chief Financial Officer
Mr. Delmar joined Avolynt as Chief Financial Officer in 2015. He previously served as Chief Financial Officer of Islet Sciences, Inc., a publicly traded biotech focused on developing therapeutic and diagnostic product candidates for diabetes indications. Prior to Islet Sciences, Mr. Delmar served as Director of Business Operations at Computer Sciences Corporation (CSC). Prior to his role at CSC, Mr. Delmar served as Chief Financial Officer of Integrity Management Consulting, a provider of major systems acquisition and program management support services to government agencies. He also served as Chief Financial Officer of ACE*COMM Corporation, a publicly held telecommunications company where he successfully completed multiple acquisitions and facilitated the sale of the company to a private equity investor. Mr. Delmar spent 22 years at Microlog Corporation, a publicly held internet software and services telecommunications company, including 15 years as an executive officer, serving most recently as Chief Financial Officer. While at Microlog, Steve successfully led the initial public offering and secondary offerings as well as multiple acquisitions. Steve earned a Bachelor of Science in Accounting from Clemson University and passed the CPA exam in Maryland.
Bentley Cheatham, Ph.D Vice President, R&D
Dr. Cheatham joined Avolynt as Vice President of Research and Development in 2015. He previously served as Chief Executive Officer of BHV Pharma, a clinical stage pharmaceutical company focusing on development of therapeutics for metabolic disease. Prior to BHV Pharma, Dr. Cheatham served as Vice President at Zen-Bio and was responsible for developing and adapting early stage platform technologies for commercialization, coordinating multi-site collaborative projects with academic and commercial entities, consulting with client companies to assist in their drug development and business goals, and communicating scientific results and business strategies/opportunities to clients and investment institutions. Dr. Cheatham also established numerous NIH-funded drug discovery programs. Prior to entering the biopharmaceutical arena, Dr. Cheatham held an academic position at the Joslin Diabetes Center at Harvard Medical School. Dr. Cheatham has published numerous peer-reviewed articles in metabolic disease. Dr. Cheatham received his Ph.D. from the University of Tennessee and did his postdoctoral work at Harvard Medical School.